Ultragenyx Pharmaceutical Inc. – Investor and Legal Developments
Company Overview
- Ticker: RARE (NASDAQ)
- Sector: Health Care – Biotechnology
- Market Cap: $2.27 billion (USD)
- Recent Close (2026‑02‑12): $20.52
- 52‑Week Range: $45.00 – $18.41
- Price‑to‑Earnings: –3.96
Ultragenyx Pharmaceutical Inc. is a biotechnology service provider headquartered in Novato, United States. The company focuses on the development of therapeutics and sialic acid for metabolic, muscular, glucuronidase, and rare genetic diseases.
1. Securities Class Action Litigation
A securities class action lawsuit was filed against Ultragenyx on behalf of shareholders who purchased common stock during the period from August 3, 2023 to December 26, 2025. The lawsuit alleges potential violations of federal securities laws, including misstatements related to the company’s earnings and financial disclosures.
| Date | Source | Key Point |
|---|---|---|
| 2026‑02‑13 | ceo.ca | Announcement of the securities fraud class action lawsuit. |
| 2026‑02‑13 | pr‑inside.com | Rosen Law Firm details the “Class Period” and invites inquiries from affected investors. |
| 2026‑02‑14 | marketscreener.com | Rosen Law Firm encourages investors to secure counsel before the April 6, 2026 filing deadline. |
| 2026‑02‑14 | ceo.ca | Kessler Topaz Meltzer & Check LLP is urged to contact investors regarding the lawsuit. |
| 2026‑02‑15 | marketscreener.com | Faruqi & Faruqi, LLP reminds investors of the April 6 deadline. |
| 2026‑02‑15 | ceo.ca | Investor alert for those with substantial losses to consider leading the lawsuit. |
| 2026‑02‑16 | archyde.com | Archyde reports that investors purchased during the Class Period are encouraged to inquire about potential violations. |
The filing deadline for the class action is April 6, 2026. Investors who experienced losses exceeding $100,000 are specifically encouraged to seek legal counsel.
2. Earnings Performance
Ultragenyx reported earnings per share of $1.29 for the most recent quarter, a figure that was below market expectations. The company’s shares gapped down on the day following the earnings announcement:
- Previous Close (2026‑02‑11): $23.50
- Open (2026‑02‑12): $21.54
- Last Traded Price (2026‑02‑12): $21.0370
- Volume (2026‑02‑12): 1,032,862 shares
The gap down reflects investor reaction to the weaker-than‑expected earnings report.
3. Investor Counsel and Legal Guidance
Multiple law firms have issued alerts encouraging Ultragenyx shareholders to engage legal representation:
- Rosen Law Firm (ranked investor rights firm) has issued several advisories urging investors to secure counsel before the April 6 filing deadline.
- Kessler Topaz Meltzer & Check LLP has been highlighted as a point of contact for investors needing guidance on the securities fraud claim.
- Robbins Geller Rudman & Dowd LLP has announced opportunities for investors with substantial losses to lead the class action lawsuit.
These advisories emphasize the importance of timely legal consultation to preserve potential claims and ensure proper participation in the lawsuit process.
4. Market Context
Ultragenyx’s share price remains within its 52‑week range, oscillating between $45.00 and $18.41. With a negative price‑to‑earnings ratio, the company’s valuation is currently below earnings expectations, reflecting market uncertainty around its financial performance and the ongoing legal challenges.
